# An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection

> **NCT04494412** · PHASE2 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 12 (estimated)

## Conditions studied

- Influenza, Human
- Arthralgia

## Interventions

- **DRUG:** Zanamivir

## Key facts

- **NCT ID:** NCT04494412
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-21
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04494412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04494412, "An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT04494412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*